Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 12 May 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 09 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Dec 2018 as reported by ClinicalTrials.gov.